Human K-ras Gene Mutations Detection Kit
Real Time PCR
CE-IVD Certificate no.：MDD-SZ-XW-160321
Cetuximab and panitumumab, as the targeted monoclonal antibodies can inhibit EGFR downstream signal transduction. Studies had shown that patients with KRAS mutations will resist cetuximab and panitumumab, FDA indicates in the instruction of cetuximab and panitumumab that such drugs are not recommended to apply to colorectal cancer patients with KRAS mutations.
NCCN clinical practice guidelines in oncology Non-Small Cell Lung Cancer (Version 4.2016) suggested that pathological assessment should include the detection of KRAS gene mutation, which is one of the reasons for drug resistance. Therefore , KRAS mutation detection is recommended before taking relevant targeted drugs.
Target Drugs and KRAS Gene
|No.||Mutation Name||Changes of Amino Acids||Changes of Bases||Cosmic ID|
|1||Gly12Asp||Glycine to Asparaginic Acids||GGT>GAT||521|
|2||Gly12Ala||Glycine to Alanine||GGT>GCT||522|
|4||Gly12Ser||Glycine to Serine||GGT>AGT||517|
|5||Gly12Arg||Glycine to Arginine||GGT>CGT||518|
|6||Gly12Cys||Glycine to Cystine||GGT>TGT||516|
|7||Gly13Asp||Glycine to Asparaginic Acids||GGC>GAC||532|
● For the patients taking EGFR-TKI,the detection results of K-ras status can be used to predict the drug efficacy.
● For the patients with metastatic colorectal cancer, the detection of K-ras status is recommended before starting cetuximab treatment.
Easy operation:One-step operation. 90 minutes of the whole process.
High Sensitivity: Accurate detection of single copies of mutated DNA samples as little as10ng genome.
Good Reproducibility: Can be performed in the general PCR Labs. Results with good reproducibility can be easily obtained without special training.
Advanced Technology: R&D based on independent patented PAP-ARMS technology.